Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 7, 2019
OncoCyte Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early ...
February 7, 2019
Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress
SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) will present preclinical and early clinical development data from its investigative drug candidate olorinab, a ...
February 7, 2019
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & ...
February 7, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2018
HOUSTON, TX and VANCOUVER, Feb. 7, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on ...
February 6, 2019
Novelion Therapeutics Subsidiary Enters Into Licensing Agreement for JUXTAPID® in Japan
VANCOUVER, British Columbia, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with ...
February 6, 2019
Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
REHOVOT, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced ...
February 6, 2019
InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
JENA, Germany and NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases ...
February 6, 2019
Orchard Therapeutics Announces Acceptance of Late-Breaking Abstracts of OTL-101 for ADA-SCID and OTL-102 for X-CGD at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR
BOSTON and LONDON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with ...
February 6, 2019
Zogenix Submits New Drug Application to U.S. Food & Drug Administration and Marketing Authorization Application to European Medicines Agency for FINTEPLA® for the Treatment of Dravet Syndrome
EMERYVILLE, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has completed its ...
February 6, 2019
Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
February 6, 2019
Combination of Veyonda® + Radiotherapy Delivers Clinical Benefits In Noxopharm’s DARRT-1 Interim Results
SYDNEY, Australia, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX:NOX) announces interim (12-week) results from the dose-ranging component of the DARRT-1 study. ...
February 6, 2019
Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan
PALO ALTO, Calif., Feb. 6, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, ...
February 6, 2019
Bionano Genomics’ Saphyr® System Used for Highly Accurate Detection of the Genetic Disorder FSHD as an Alternative to Southern Blot
SAN DIEGO, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.  (BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ...
February 6, 2019
Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia
NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its ...
February 6, 2019
CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
LOS ANGELES, Feb. 6, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, highlighted positive Phase 2/3 clinical trial data ...
February 6, 2019
Quantum Genomics Announces the Publication of Two Scientific Articles Confirming the Efficacy of Firibastat for Heart Failure
PARIS and NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of ...
February 5, 2019
BioInvent CSO to Present F.I.R.S.T.™ Discovery Platform at SLAS2019
LUND, Sweden, Feb. 5, 2019 BioInvent International AB (OMXS:BINV) announces today that its Chief Scientific Officer, Björn Frendéus, will hold a presentation about its phenotypic ...
February 5, 2019
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2018 Financial Results and Host Conference Call on February 12
REHOVOT, Israel, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release ...
February 5, 2019
CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference
MONMOUTH JUNCTION, N.J., Feb. 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in ...
February 5, 2019
Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc., (CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
Page 15 of 138